Tucatinib for the Treatment of HER2+ Breast Cancer

Описание к видео Tucatinib for the Treatment of HER2+ Breast Cancer

Ian Krop, MD, PhD, reviews the results from the HER2CLIMB trial which evaluated addition of a novel HER2-targeted TKI, tucatinib, to trastuzumab and capecitabine in patients with heavily pre-treated HER2+ metastatic breast cancer, and the hope for FDA approval of this agent.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Комментарии

Информация по комментариям в разработке